Treating leukemia: differentiation therapy for mIDH2 AML

摘要：

While the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) has been a remarkably successful example for differentiation therapy of cancer,the recently developed therapeutics of mutant IDH2 (mIDH2)-associated leukemia by specific mIDH2 inhibitors is launching another promising campaign.Interestingly,a recent study in Cell Research by Mugoni et al.demonstrated a sensitivity of the mIDH2 leukemia to the APL-like ATRA/ATO combination therapy,narrating a convergence of two tales.

所属期刊栏目：29

在线出版日期：2019-07-29（万方平台首次上网日期，不代表论文的发表时间）

页数：共2页

页码：427-428